ABN AMRO Bank N.V. Sells 45,844 Shares of Stryker Corporation $SYK

ABN AMRO Bank N.V. trimmed its stake in shares of Stryker Corporation (NYSE:SYK) by 7.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 549,219 shares of the medical technology company’s stock after selling 45,844 shares during the quarter. Stryker makes up 2.0% of ABN AMRO Bank N.V.’s holdings, making the stock its 19th biggest holding. ABN AMRO Bank N.V.’s holdings in Stryker were worth $182,225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sankala Group LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $26,000. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter valued at $26,000. United Financial Planning Group LLC acquired a new stake in Stryker during the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker in the 4th quarter valued at about $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the topic of several research analyst reports. Barclays cut their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. BTIG Research dropped their price target on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. William Blair restated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, UBS Group decreased their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Stock Performance

Shares of SYK stock opened at $332.31 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a fifty day simple moving average of $311.10 and a two-hundred day simple moving average of $339.93. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The firm has a market capitalization of $127.39 billion, a PE ratio of 38.46, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the transaction, the vice president owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.